New Axon GenePix(R) microarray scanners and Arcturus(R) Laser Capture Microdissection instrument improve research speed and precision SUNNYVALE, CA, May 14 /PRNewswire-FirstCall/ -- MDS Analytical Technologies, a leader in innovative solutions for drug discovery and life sciences research, announced today the release of three new molecular biology instruments designed to advance genomics and microgenomics discoveries for life sciences researchers. These instruments provide scientists flexible and open platforms to perform sensitive and specific molecular analysis in a number of fields, including stem cell research, cancer research, proteomics, drug discovery and many others. Two new microarray scanners, the Axon GenePix(R) 4300A and the Axon GenePix(R) 4400A, represent the latest in a long line of industry-leading microarray detection and analysis systems from MDS Analytical Technologies. These newest platforms improve the efficiency of research experiments, reduce the cost per data point, and offer the broadest applicability in the microarray industry. For researchers using laser capture microdissection (LCM), a method for isolating cells under a microscope, the new, next-generation ArcturusXT(TM) instrument uses the latest advances in microscope technology by employing the Nikon Eclipse Ti-E inverted research microscope as its base. This new technology improves speed, precision and flexibility during the microdissection process - shortening the length of time required for experiments and expanding application potential through an increased range of available options. "These new products continue our tradition of innovation and excellence, offering reliability, flexibility, and high performance solutions for life sciences researchers," commented Dr. Andy Boorn, president of MDS Analytical Technologies. "The Axon GenePix 4300A and 4400A scanners provide customers with the ability to run the most advanced microarray applications in the industry, which keeps them at the forefront of this technology field. The new ArcturusXT system gives us a solid platform upon which to offer increasingly beneficial features to researchers who use our LCM technology." About MDS Analytical Technologies MDS Analytical Technologies is a newly established MDS Inc. business unit and is a world-class organization comprised of two main lines of business. The Sciex product portfolio offers proven market leadership in mass spectrometry through its joint ventures with two of the world's leading analytical instrumentation and life sciences companies, Applied Biosystems, a business of the Applera Corporations and PerkinElmer Inc. Molecular Devices' product portfolio is the gold standard in high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Find out more at http://www.moleculardevices.com/ or http://www.mdssciex.com/. About MDS Inc. MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS, Inc. has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a day. Note to Editors: Click here for a detailed Product Fact Sheet on the Axon GenePix(R) 4300A, Axon GenePix(R) 4400A and the ArcturisXT(TM). DATASOURCE: MDS Analytical Technologies CONTACT: Media: Cheri Salazar, Director, Global Marketing Communications, Molecular Devices, now part of MDS Analytical Technologies, (408) 548-6316, ; Investors: Kim Lee, Senior Director, Investor Relations, MDS Inc., (416) 213-4721,

Copyright